Company news
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) news
Recursion Pharmaceuticals, Inc. news releases on 6ix. Latest, Sep 3, 2024: Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational…
Press releases — page 2
Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability
September 2, 2024
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
August 7, 2024
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
August 7, 2024
Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities
August 7, 2024
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
August 4, 2024
Recursion Announces Proposed Offering of Class A Common Stock
June 25, 2024
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
June 25, 2024
Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data
June 23, 2024
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
May 28, 2024
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
May 23, 2024
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
May 12, 2024
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
May 8, 2024
Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9
May 1, 2024
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
April 15, 2024
Recursion Publishes Annual Environmental, Social and Governance Report
March 25, 2024
Recursion Announces Plans to Open New Office in London
March 10, 2024
Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community
February 29, 2024
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results
February 26, 2024
Recursion to Host Public L(earnings) Call on February 27
February 19, 2024
Recursion Unveils LOWE Drug Discovery Software at the J.P. Morgan Healthcare Conference
January 7, 2024
Recursion Adds New Chemical Entity Targeting Fibrotic Diseases to Late Discovery Pipeline
January 3, 2024
Recursion to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8
January 2, 2024
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
December 19, 2023
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
November 8, 2023
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
November 8, 2023
Bayer and Recursion Focus Research Collaboration on Oncology
November 8, 2023
Bayer and Recursion focus research collaboration on Oncology
November 8, 2023
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
September 4, 2023
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
August 7, 2023
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
August 7, 2023
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
July 25, 2023
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
July 11, 2023
Recursion Celebrates Opening of Its Canadian Headquarters in Toronto with Government Officials and the Biotech Ecosystem
June 25, 2023
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
June 12, 2023
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
May 15, 2023
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
May 7, 2023
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
May 7, 2023
Recursion Publishes Second Annual Environmental, Social and Governance Report
March 27, 2023
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
January 25, 2023
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results
November 7, 2022
Recursion Announces $150 Million Private Placement to New and Existing Investors, led by Kinnevik AB
October 24, 2022
Recursion Initiates Two Additional Clinical Trials For a Total of Four in 2022
September 12, 2022
Recursion Receives ISS ESG Prime Rating and Plans to Participate in the Goldman Sachs Global Sustainability Forum
August 17, 2022
Recursion Provides Business Updates and Reports Second Quarter 2022 Financial Results
August 8, 2022
Recursion is Granted EU Orphan Drug Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
July 20, 2022
Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference
June 19, 2022
Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results
May 9, 2022
Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis
April 10, 2022
Recursion Publishes First Environmental, Social and Governance (ESG) Report
March 23, 2022
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results
March 22, 2022